Compare AROW & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROW | DNA |
|---|---|---|
| Founded | 1851 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.5M | 599.0M |
| IPO Year | 1995 | N/A |
| Metric | AROW | DNA |
|---|---|---|
| Price | $41.29 | $7.85 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $28.00 | $8.50 |
| AVG Volume (30 Days) | 103.1K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ 49.72 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.36 | N/A |
| Revenue Next Year | $18.26 | N/A |
| P/E Ratio | $51.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.84 | $5.37 |
| 52 Week High | $42.70 | $17.58 |
| Indicator | AROW | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 37.05 |
| Support Level | $35.26 | $7.59 |
| Resistance Level | $42.44 | $10.27 |
| Average True Range (ATR) | 1.15 | 0.73 |
| MACD | -0.04 | -0.23 |
| Stochastic Oscillator | 63.25 | 5.37 |
Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services, including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of the company's revenue is interest income, fees, commission earned through its subsidiaries.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.